122 related articles for article (PubMed ID: 38215931)
1. Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
Vysochinskaya V; Zabrodskaya Y; Dovbysh O; Emelyanov A; Klimenko V; Knyazev N; Terterov I; Egorova M; Bogdanov A; Maslov M; Vasin A; Dubina M
Biochimie; 2024 Jun; 221():1-12. PubMed ID: 38215931
[TBL] [Abstract][Full Text] [Related]
2.
Kc R; Thapa B; Ubeda A; Jiang X; Uludağ H
Stem Cells Dev; 2019 Jun; 28(11):734-744. PubMed ID: 30585758
[TBL] [Abstract][Full Text] [Related]
3. siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Freire JM; Rego de Figueiredo I; Valle J; Veiga AS; Andreu D; Enguita FJ; Castanho MA
J Control Release; 2017 Jan; 245():127-136. PubMed ID: 27890856
[TBL] [Abstract][Full Text] [Related]
4. siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
Valencia-Serna J; Kucharski C; Chen M; Kc R; Jiang X; Brandwein J; Uludağ H
J Control Release; 2019 Sep; 310():141-154. PubMed ID: 31430499
[TBL] [Abstract][Full Text] [Related]
5. Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells.
Arthanari Y; Pluen A; Rajendran R; Aojula H; Demonacos C
J Control Release; 2010 Aug; 145(3):272-80. PubMed ID: 20403398
[TBL] [Abstract][Full Text] [Related]
6. siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Valencia-Serna J; Aliabadi HM; Manfrin A; Mohseni M; Jiang X; Uludag H
Eur J Pharm Biopharm; 2018 Sep; 130():66-70. PubMed ID: 29913272
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Jyotsana N; Sharma A; Chaturvedi A; Budida R; Scherr M; Kuchenbauer F; Lindner R; Noyan F; Sühs KW; Stangel M; Grote-Koska D; Brand K; Vornlocher HP; Eder M; Thol F; Ganser A; Humphries RK; Ramsay E; Cullis P; Heuser M
Ann Hematol; 2019 Aug; 98(8):1905-1918. PubMed ID: 31104089
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
Zhu XS; Lin ZY; Du J; Cao GX; Liu G
Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
[TBL] [Abstract][Full Text] [Related]
9. Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Valencia-Serna J; Gul-Uludağ H; Mahdipoor P; Jiang X; Uludağ H
J Control Release; 2013 Dec; 172(2):495-503. PubMed ID: 23726887
[TBL] [Abstract][Full Text] [Related]
10. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment.
Mendonça LS; Firmino F; Moreira JN; Pedroso de Lima MC; Simões S
Bioconjug Chem; 2010 Jan; 21(1):157-68. PubMed ID: 20000596
[TBL] [Abstract][Full Text] [Related]
11. Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia.
Vysochinskaya V; Dovbysh O; Gorshkov A; Brodskaia A; Dubina M; Vasin A; Zabrodskaya Y
Biomolecules; 2024 May; 14(6):. PubMed ID: 38927048
[TBL] [Abstract][Full Text] [Related]
12. Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Zaree Mahmodabady A; Javadi HR; Kamali M; Najafi A; Hojati Z
Iran Biomed J; 2010; 14(1-2):1-8. PubMed ID: 20683492
[TBL] [Abstract][Full Text] [Related]
13. Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models.
Ansari AS; K C R; Morales LC; Nasrullah M; Meenakshi Sundaram DN; Kucharski C; Jiang X; Brandwein J; Uludağ H
J Control Release; 2024 Mar; 367():821-836. PubMed ID: 38360178
[TBL] [Abstract][Full Text] [Related]
14. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
[No Abstract] [Full Text] [Related]
15. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Woessner DW; Lim CS
Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
[TBL] [Abstract][Full Text] [Related]
16. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Khorashad JS; Eiring AM; Mason CC; Gantz KC; Bowler AD; Redwine HM; Yu F; Kraft IL; Pomicter AD; Reynolds KR; Iovino AJ; Zabriskie MS; Heaton WL; Tantravahi SK; Kauffman M; Shacham S; Chenchik A; Bonneau K; Ullman KS; O'Hare T; Deininger MW
Blood; 2015 Mar; 125(11):1772-81. PubMed ID: 25573989
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Yang C; Panwar N; Wang Y; Zhang B; Liu M; Toh H; Yoon HS; Tjin SC; Chong PH; Law WC; Chen CK; Yong KT
Nanoscale; 2016 Apr; 8(17):9405-16. PubMed ID: 27092903
[TBL] [Abstract][Full Text] [Related]
18. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
19. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
20. Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy.
Remant KC; Thapa B; Valencia-Serna J; Domun SS; Dimitroff C; Jiang X; Uludağ H
J Biomed Mater Res A; 2020 Mar; 108(3):565-580. PubMed ID: 31714657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
